Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
44.20
-0.56 (-1.25%)
At close: May 12, 2025, 4:00 PM
45.12
+0.92 (2.08%)
After-hours: May 12, 2025, 7:13 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $78.34M in the quarter ending March 31, 2025, with 183.68% growth. This brings the company's revenue in the last twelve months to $233.67M, up 449.03% year-over-year. In the year 2024, Tarsus Pharmaceuticals had annual revenue of $182.95M with 948.62% growth.
Revenue (ttm)
$233.67M
Revenue Growth
+449.03%
P/S Ratio
7.30
Revenue / Employee
$723,449
Employees
323
Market Cap
1.86B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TARS News
- 10 hours ago - Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off - Seeking Alpha
- 4 days ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PRNewsWire
- 11 days ago - Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements - GlobeNewsWire
- 18 days ago - Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - GlobeNewsWire
- 20 days ago - Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewsWire